Axsome Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2016 Annual Meeting of Stockholders held on June 10, 2016. Axsome Therapeutics, Inc. is a Delaware corporation headquartered in New York, New York.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 19,149,417 shares entitled to vote, 14,931,422 shares (approximately 78%) were represented, constituting a quorum. Two proposals were submitted and approved:
- Proposal 1: Election of Class I Director
- Director Elected: Roger Jeffs, Ph.D. (Term until 2019 annual meeting).
- Votes For: 14,241,580
- Votes Withheld: 457,171
- Broker Non-Votes: 232,671
- Proposal 2: Ratification of Independent Auditor
- Auditor: Ernst & Young LLP (for fiscal year ending December 31, 2016).
- Votes For: 14,926,041
- Votes Against: 5,291
- Votes Abstaining: 90
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 27, 2016.
Investor Verification Checklist
- Verify the term length and qualifications of the newly elected director, Roger Jeffs, Ph.D.
- Confirm the engagement terms and scope of work with the newly ratified auditor, Ernst & Young LLP.
- Review the Schedule 14A Proxy Statement filed on April 27, 2016, for detailed background on the proposals.